Nori Feline FGF23 ELISA Kit

$461.00$832.00

DataSheet   

This ELISA kit is for quantification of FGF23 in cat. This is a quick ELISA assay that reduces time to 50% compared to the conventional method, and the entire assay only takes 3 hours. This assay employs the quantitative sandwich enzyme immunoassay technique and uses biotin-streptavidin chemistry to improve the performance of the assays. An antibody specific for FGF23 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any FGF23 present is bound by the immobilized antibody. After washing away any unbound substances, a detection antibody specific for FGF23 is added to the wells. Following wash to remove any unbound antibody reagent, a detection reagent is added. After intensive wash a substrate solution is added to the wells and color develops in proportion to the amount of FGF23 bound in the initial step. The color development is stopped, and the intensity of the color is measured.

Alternative names for FGF23: Fibroblast growth factor 23, HYPF

 

 

This product is for Laboratory Research Use Only not for diagnostic and therapeutic purposes or any other purposes.

CAT: GR188395 Categories: , Tag:
Clear
View cart

Description

Nori Feline FGF23 ELISA Kit Summary

Alternative names for FGF23: Fibroblast growth factor 23, HYPF

Alternative names for feline: cat

Assay Type Solid Phase Sandwich ELISA
Format 96-well Microplate or 96-Well Strip Microplate
Method of Detection Colorimetric
Number of Targets Detected 1
Target Antigen Accession Number QA0A337SEX6
Assay Length 3 hours
Quantitative/Semiquantitative Quantitative
Sample Type Plasma, Serum, Cell Culture, Urine, Cell/Tissue Lysates, Synovial Fluid, BAL,
Recommended Sample Dilution (Plasma/Serum) No dilution for sample <ULOQ; sufficient dilution for samples >ULOQ
Sensitivity 15 pg/mL
Detection Range 78-5000 pg/mL
Specificity Feline FGF23
Cross-Reactivity < 0.5% cross-reactivity observed with available related molecules, < 50% cross-species reactivity observed with species tested.
Interference No significant interference observed with available related molecules
Storage/Stability 4 ºC for up to 6 months
Usage For Laboratory Research Use Only. Not for diagnostic or therapeutic use.
Additional Notes The kit allows for use in multiple experiments.

 

Standard Curve

Kit Components
1. Pre-coated 96-well Microplate
2. Biotinylated Detection Antibody
3. Streptavidin-HRP Conjugate
4. Lyophilized Standards
5. TMB One-Step Substrate
6. Stop Solution
7. 20 x PBS
8. Assay Buffer

Other Materials Required but not Provided:
1. Microplate Reader capable of measuring absorption at 450 nm
2. Log-log graph paper or computer and software for ELISA data analysis
3. Precision pipettes (1-1000 µl)
4. Multi-channel pipettes (300 µl)
5. Distilled or deionized water

Protocol Outline
1. Prepare all reagents, samples and standards as instructed in the datasheet.
2. Add 100 µl of Standard or samples to each well and incubate 1 h at RT.
3. Add 100 µl of Working Detection Antibody to each well and incubate 1 h at RT.
4. Add 100 µl of Working Streptavidin-HRP to each well and incubate 20 min at RT.
5. Add 100 µl of Substrate to each well and incubate 5-30 min at RT.
6. Add 50 µl of Stop Solution to each well and read at 450 nm immediately.

Background: 

Fibroblast growth factor 23 (FGF23) is a protein that in humans is encoded by the FGF23 gene.[1] FGF23 is a member of the FGF family which is responsible for phosphate and vitamin D metabolism.[2][3] The main function of FGF23 seems to be regulation of phosphate concentration in plasma. FGF23 is secreted by osteocytes in response to elevated calcitriol. FGF23 acts on the kidneys, where it decreases the expression of NPT2, a sodium-phosphate cotransporter in the proximal tubule.[4] Thus, FGF23 decreases the reabsorption and increases excretion of phosphate. FGF23 may also suppress 1-alpha-hydroxylase, reducing its ability to activate vitamin D and subsequently impairing calcium absorption.[3] Mutations in FGF23 that render the protein resistant to proteolytic cleavage leads to increased activity of FGF23 and the renal phosphate loss found in the human disease autosomal dominant hypophosphatemic rickets. FGF23 is also overproduced by some types of tumors, such as the benign mesenchymal neoplasm Phosphaturic mesenchymal tumor causing tumor-induced osteomalacia, a paraneoplastic syndrome.[5] Loss of FGF23 activity is thought to lead to increased phosphate levels and the clinical syndrome of familial tumor calcinosis. This gene was identified by its mutations associated with autosomal dominant hypophosphatemic rickets.

References

  1. Yamashita T, et al. (2000). Biochem. Biophys. Res. Commun. 277 (2): 494–8.
  2. Fukumoto S (2008). Intern. Med. 47 (5): 337–43.
  3. Perwad F (2007). Am J Physiol Renal Physiol. 293 (5): F1577–83.
  4. Jüppner H (2011). “Phosphate and FGF-23”. Kidney Int. Suppl. 79 (121): S24–7.
  5. Zadik Y, Nitzan DW (2011). Oral Oncol. 48 (2): e9–10.

Product Citations

 

Reviews

There are no reviews yet.


Be the first to review “Nori Feline FGF23 ELISA Kit”